Neurosense Therapeutics (NASDAQ:NRSN) focuses on developing treatments for neurodegenerative diseases, particularly those without current effective therapies. Their work revolves around pioneering approaches to combat conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, aiming to significantly improve the quality of life for patients. Projects include innovative drug development and clinical trials designed to test the efficacy and safety of new therapies. Neurosense's objectives are deeply rooted in the pursuit of breakthroughs that can halt or reverse the progression of debilitating neurological conditions, demonstrating their commitment to advancing medical science and patient care. Through their dedicated research and development efforts, Neurosense strives to address some of the most challenging aspects of neurodegenerative disease treatment.